Basic Study
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Exp Med. Sep 20, 2023; 13(4): 75-94
Published online Sep 20, 2023. doi: 10.5493/wjem.v13.i4.75
Personalized clinical managements through exploring circulating neural cells and electroencephalography
Parvin Mehdipour, Nima Fathi, Masoud Nosratabadi
Parvin Mehdipour, Department of Medical Genetics, Tehran University of Medical Sciences, Tehran 14176-1315, Iran
Nima Fathi, Neuro-Science, Paarand Specialized Center for Human Enhancement, Tehran 157699304, Iran
Masoud Nosratabadi, Department of Research, Paarand Specialized Center for Human Enhancement, Tehran 157699304, Iran
Author contributions: Mehdipour P designed the research, analytical strategy and contributed the data on genetics and cell biology; Fathi N and Nosratabadi M, and Mehdipour P contributed equally to this work and analysed data of the brain channels; all authors wrote, have read, and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by investigation of the fundamental pattern in the brain channels’ EEG of five apparently healthy individuals, with ethics ID “IR.IUMS.REC.1399.310”.
Institutional animal care and use committee statement: This study was not involved any animal experiments.
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
ARRIVE guidelines statement: The authors have read the ARRIVE guidelines, and the manuscript was prepared and revised according to the ARRIVE guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Parvin Mehdipour, PhD, Full Professor, Department of Medical Genetics, Tehran University of Medical Sciences, Pour Sina Ave, Tehran 14176-1315, Iran. mehdipor@tums.ac.ir
Received: January 20, 2023
Peer-review started: January 20, 2023
First decision: April 13, 2023
Revised: May 22, 2023
Accepted: July 11, 2023
Article in press: July 11, 2023
Published online: September 20, 2023
Processing time: 238 Days and 4.2 Hours
Abstract
BACKGROUND

Since an initial diagnosis of Alzheimer disease (AD) in 1907, early detection, was unavailable through 116 years. Up-regulation of V-Ets erythroblastosis virus E26 oncogene homolog 2 (Ets2) is capable to enhance neuronal susceptibility and degeneration. Protein expression (PE) of Ets2 has functional impact on AD and Down’s syndrome, with diverse intensity. PE of Ets2 has an influential pathogenic impact on AD. Clinical aspects of neurological disorders directly interact with psychological maladies. However, deterioration requires an early management including programmed based protection.

AIM

To include cell biology in neuro-genetics; personalized, prognostics, predictive, preventive, predisposing (5xP) platform, accompanied by stratifying brain channels behavior pre- and post-intervention by light music in the AD-patients.

METHODS

Include exploration of PE assay and electroencephalography of brain channels. The processes are applied according to: (1) Triangle style, by application of cellular network; and (2) PE assay of Ets2 in the peripheral blood of the patients with AD, by Manual single cell based analysis, and Flow-cytometry. (1) Applying the Genetic counselling and pedigree analysis; (2) considering the psychological status of the referral cases; (3) considering the macro-and/or micro-environmental factors; (4) performing the required Genetics’ analysis; and (5) applying the required complementary test(s).

RESULTS

PE of Ets2 has pathogenic role in AD. PE unmasked the nature of heterogeneity/diversity/course of evolution by exploring Ets2, D1853N polymorphism in Ataxia Telangiectasia mutated gene (ATM), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and course of evolution at the single cell level of the brain. Ets2 revealed different cellular behavior in the blood and suggested the strategy as ‘Gene Product-Based Therapy’ and the personalized managements for the patients. PE reflected weak expression of ATM, mosaic pattern of Ets2; remarkable expression of VEGF and EGF by highlighting an early detective platform, considering circulating neural cells (CNCs) and the required molecular investigation, for the target individual(s) predisposed to AD or other neural disease including brain neoplasia. Brain channels-cooperation with diverse/interactive-ratios lead to strategic balancing for improving the life-quality in AD.

CONCLUSION

We highlighted application of the single CNCs and correlated Ratio based between Brain channels by providing the 5xP personalized clinical management model for an early detection and therapy of the patients with AD and their targeted/predisposed relatives. Novel-evolutionary/hypothetic/heterogenic-results in brain-channels offer personalizd/constructive markers with unlimited cooperation in health and disease.

Keywords: Alzheimer; Protein expression; Brain channels; Predictive/early detection

Core Tip: The provided outcomes emphasize on the personalized/classified/functional/single cell based/complementary insights, and systematic strategy in Neuro-Science. The successful bridging approach between Neuro-Science and Medicine requires: (1) The combination of the molecular and functional insights at single cell level; (2) by emphasizing on the course of evolution; and (3) to expedite towards unmasking the functional modifications in the blood stream of the patients with neurological disorders including Alzheimer disease (AD). However, exploration of the circulating neural cells accelerate to unmask the course of evolution by providing the personalized and translatable model to the target based therapy. Let’s improve the life quality of the patients with neurological disorders including AD with simply the light music which corresponds with 40 Hz in gamma sensory stimulation therapy. It is essential to differentiate between neurological- and neuro-psychiatric diseases. Surprisingly, we offer an early detection of the stem cells, including the neural CD133 at fetal period, i.e., as early as 8-9 wk, or later through the circulating fetal cells in the maternal blood stream.